Chemotherapy is now employed in earlier-stage disease in neoadjuvant, adjuvant, and combined-modality treatments. The aim of this article is to review the current systemic treatments for NSCLC.
Elizabeth S. Waxman, RN, MSN, NP-C
Advertisement
Articles by Elizabeth S. Waxman, RN, MSN, NP-C
Hypersensitivity/infusion reactions can be caused by monoclonal antibodies and chemotherapeutic agents. Immediate interventions are often required.
Advertisement
Latest Updated Articles
An Infusion Reaction to CetuximabPublished: April 18th 2011 | Updated:
Current Treatment Options for Non–Small-Cell Lung CancerPublished: August 27th 2012 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice
2
FDA Approves Revumenib in R/R NPM1-Mutant AML
3
FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma
4
Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment
5
